EBITDA at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s EBITDA?
- Taysha Gene Therapies, Inc. (TSHA) reported EBITDA of -$43.19M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s EBITDA changed year-over-year?
- Taysha Gene Therapies, Inc.'s EBITDA decreased by 104.3% year-over-year, from -$21.14M to -$43.19M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s EBITDA has grown at a -10.8% compound annual growth rate (CAGR), from -$172.74M to -$109.42M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.